Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Air Products & Chemicals, Inc. (APD) vs Cassava Sciences Inc (FLNA) Price & Performance

Air Products & Chemicals, Inc.Trade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Air Products & Chemicals, Inc. vs Cassava Sciences Inc — how do they compare? Air Products & Chemicals, Inc. trades at $302.53 (market cap $66.70B), while Cassava Sciences Inc trades at $1.16 (market cap $57.49M). The key difference: Air Products & Chemicals, Inc. is far larger — about 1160.2× Cassava Sciences Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.42% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

APDFLNA
Market Cap
$66.70B$57.49M
Sector
Basic MaterialsHealth
52-Week High
$314.19$4.64
52-Week Low
$230.42$1.16
Enterprise Value
$84.11B-$29.09M
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Air Products & Chemicals, Inc.

APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.

The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.

Cassava Sciences Inc

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Air Products & Chemicals, Inc.

Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.

Read more on APD

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA